BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1193 related articles for article (PubMed ID: 16397977)

  • 1. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
    Cortet B
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antifracture efficacy of alendronate.
    Seeman E
    Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
    Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY
    Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
    Dimai HP
    Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.